New targeted combination in people with relapsed acute myeloid leukemia shows promise

MedicalXpress | يون 04, 2026

New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational treatment approach using the targeted therapy ziftomenib for patients with a difficult-to-treat form of acute myeloid leukemia (AML). The findings, published in the journal Blood, show encouraging results from a three-drug combination therapy in patients whose leukemia has returned or not responded to prior treatment.